Study Evaluating Rimonabant Efficacy in Insulin-Treated Diabetic Patients(ARPEGGIO)
Completed · Phase 3 · Has a placebo group
Conditions studied: Type 2 Diabetes Mellitus
In brief
Primary: Effect on HbA1c over 48 weeks in insulin-treated patients with type 2 diabetes Secondary: Effect on glucose, total daily insulin dose, body weight, waist circumference, HDL-cholesterol, triglycerides - Safety, tolerability
Key facts
- Study ID
- NCT00288236
- Run by
- Sanofi
- People needed
- 368
- Starts
- 2006-01-01
- Expected to finish
- 2007-07-01
- Last updated by the study team
- 2009-04-07
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Male or female patients aged greater than or equal to 18 years.
- Diagnosis of type 2 diabetes as defined by WHO criteria.
- Type 2 diabetes treated with insulin for at least 3 months (insulin dose of at least 30 U/day for at least 4 weeks).
- HbA1C greater than or equal to 7%.
- Having signed the informed consent form.
You may not qualify if…
- General:
- Weight loss > 5 kg within 3 months prior to screening visit.
- Pregnancy or lactation.
- Absence of medically approved contraceptive methods for females of childbearing potential.
- Administration of other investigational drugs within 30 days prior to screening visit.
- Previous participation in a Rimonabant study.
- Presence or history of allergic reaction or intolerance to multiple drugs.
- Related to endocrine and metabolic disorders:
- Presence of any clinically significant endocrine disease according to the Investigator.Note: euthyroid patients on replacement therapy will be included if the dosage of thyroxine is stable for at least 3 months prior to screening visit.
- Fasting C-peptide < 1.0 ng/mL.
- Related to other disorders:
- Presence of any severe medical or psychological condition that in the opinion of the Investigator would compromise the patient's safety or successful participation in the study.
- Presence or history of cancer within the past 5 years with the exception of adequately treated localized basal cell skin cancer or in situ uterine cervical cancer.
- Related to laboratory findings:
- Positive test for hepatitis B surface antigen and/or hepatitis C antibody.
- Abnormal TSH level (TSH > ULN or < LLN).
- Positive urine pregnancy test.
- Related to previous or concomitant medications:
- Antidiabetic drugs other than insulin within 3 months prior to screening visit.
- Drugs affecting weight (e.g., sibutramine, orlistat, herbal preparations, etc).
Where it is running
- Sanofi-Aventis — Bridgewater, New Jersey, United States
- Sanofi-Aventis — Buenos Aires, Argentina
- Sanofi-Aventis — Lane Cove, Australia
- Sanofi-Aventis — Laval, Canada
- Sanofi-Aventis — Providencia, Chile
- Sanofi-Aventis — Paris, France
- Sanofi-Aventis — Berlin, Germany
- Sanofi-Aventis — Milan, Italy
- Sanofi-Aventis — Gouda, Netherlands
- Sanofi-Aventis — Moscow, Russia
- Sanofi-Aventis — Midrand, South Africa
- Sanofi-Aventis — Guildford, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.